Anti-Human CD25 (Camidanlumab) - Fc Muted™ - 500 µg

Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

CD25 is the alpha-chain of the interleukin-2 receptor1, which regulates normal immunefunction2, and is involved in signal transduction, cell growth and survival1. CD25 isconsidered an attractive target for conjugated antibody chemotherapeutic developmentbecause it is overexpressed in various hematologic malignancies and is associated withpoor prognosis. Antibody drug conjugates (ADC) use tumor-associated surface antigens to specificallytarget cancer cells with cytotoxic agents. Human therapeutic grade Camidanlumab is anADC composed of a human CD25-directed antibody (HuMax-TAC) that is maleimide-conjugated at reduced interchain cysteines via a cathepsin-cleavable valine-alaninelinker to a PBD toxin warhead (SG3199)3. Camidanlumab has a strong binding affinity to CD25-positive human anaplastic largecell lymphoma derived cell lines. This research grade biosimilar has the same specificityas the original therapeutic antibody but lacks the conjugated PBD toxin warhead.

≥ 5.0 mg/ml

CD25 is expressed by approximately 30% of human peripheralblood B cells, particularly those belonging to the memory B cell population. Additionally, CD25 is expressed on the cell surface of many lymphomas, including classical Hodgkinlymphoma and non-Hodgkin lymphoma.